Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease
Authors' conclusion
None of the three treatments increased the risk of RA-associated ILD progression, except for LEF, which increased the risk of ILD progression in patients with severe ILD.
Study context
- Population
- Patients with RA-associated interstitial lung disease (ILD), Korean RA-ILD cohort, multiple centres, enrolled 2015–2018, followed for 3 years64 with ILD progression
- Participants
- 143 patients
- Exposure
- MTX, LEF and tacrolimus use and ILD progression
- Outcome
- ILD progression: decrease of ≥10% in FVC, decrease of ≥15% in DLCO, or death from respiratory failure
Methodological detailsmulticentre
- Multicentre
Main finding
As reported in the abstract
ILD progression · median follow-up 33 months
Adjusted hazard ratio (95% CI)
MTX
1.06(0.59–1.89)
LEF
1.75(0.88–3.46)
Tacrolimus
0.94(0.52–1.72)
Observational data: associations, not effects.
Further findings
ILD progression in subgroups with poor lung function
| aHR (95% CI) | ||
|---|---|---|
| LEF | 8.42 (2.61–27.15) | |
| 0.050.21520Adjusted hazard ratio (log scale) |
Factors independently associated with ILD progression
- Older age, male sex, shorter RA duration, higher RA disease activity and extensive disease at baseline independently associated with ILD progression
Original publication
Methotrexate, leflunomide and tacrolimus use and the progression of rheumatoid arthritis-associated interstitial lung disease. Rheumatology (Oxford). Published 17 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →